Zoledronat Onco Labatec 4 mg/5 ml, solution à diluer pour perfusion

7680630120014 CH-63012 Lösung
Zoledronat Onco Labatec 4 mg/5 ml, solution à diluer pour perfusion
Zoledronat Onco Labatec 4 mg/5 ml, solution à diluer pour perfusion
Zoledronat Onco Labatec 4 mg/5 ml, solution à diluer pour perfusion
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Lösung
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
14/12/2024
Summary of Product Characteristics
Français
14/12/2024
Summary of Product Characteristics
Italien
14/12/2024

Detailed composition

Substance Quantity Type Category
(N/A)
4.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
6.41 MG Substance HBESI
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 134.10
Specialties list
Yes
Generic
Yes
SL addition date: 01/07/2013

Authorization holder

Labatec Pharma SA

1217 Meyrin

Authorization information

Swissmedic authorization number
63012
Drug name
Zoledronat Onco Labatec 4 mg/5 ml, solution à diluer pour perfusion
Galenic form
KOINF
ATC Code
M05BA08
Authorization status
Z
Dispensing category
B
First authorization
16/04/2013
Authorization expiration date
31/12/9999
IT Number
07.99.0.
Domain
Human medicine

Package details

Description (FR)
ZOLEDRONAT Onco Labatec 4 mg/5ml flac 5 ml
Description (DE)
ZOLEDRONAT Onco Labatec 4 mg/5ml Durchstf 5 ml
Market launch
16/04/2013
Narcotic (BTM)
No

Original drug

Aclasta, Infusionslösung
GTIN: 7680573630014
CHF 254.45
View original